- Home
- AGL vs PHVS Comparison
AGL vs PHVS Comparison
Compare AGL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- PHVS
- Stock Information
- Founded
- AGL 2016
- PHVS 2015
- Country
- AGL United States
- PHVS Netherlands
- Employees
- AGL N/A
- PHVS N/A
- Industry
- AGL Managed Health Care
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- PHVS Health Care
- Exchange
- AGL Nasdaq
- PHVS Nasdaq
- Market Cap
- AGL 894.1M
- PHVS 1.0B
- IPO Year
- AGL 2021
- PHVS 2021
- Fundamental
- Price
- AGL $2.10
- PHVS $18.61
- Analyst Decision
- AGL Hold
- PHVS Strong Buy
- Analyst Count
- AGL 18
- PHVS 5
- Target Price
- AGL $4.38
- PHVS $40.60
- AVG Volume (30 Days)
- AGL 3.6M
- PHVS 106.8K
- Earning Date
- AGL 11-07-2024
- PHVS 11-13-2024
- Dividend Yield
- AGL N/A
- PHVS N/A
- EPS Growth
- AGL N/A
- PHVS N/A
- EPS
- AGL N/A
- PHVS N/A
- Revenue
- AGL $5,594,117,000.00
- PHVS N/A
- Revenue This Year
- AGL $41.65
- PHVS N/A
- Revenue Next Year
- AGL $10.30
- PHVS N/A
- P/E Ratio
- AGL N/A
- PHVS N/A
- Revenue Growth
- AGL 54.10
- PHVS N/A
- 52 Week Low
- AGL $1.50
- PHVS $15.37
- 52 Week High
- AGL $13.45
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- AGL 45.24
- PHVS 40.29
- Support Level
- AGL $1.92
- PHVS $17.93
- Resistance Level
- AGL $2.33
- PHVS $20.17
- Average True Range (ATR)
- AGL 0.18
- PHVS 1.53
- MACD
- AGL 0.02
- PHVS -0.15
- Stochastic Oscillator
- AGL 25.38
- PHVS 14.38
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .